Everything below concerns synthetic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-09. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
== Leukotrienes in asthma == Leukotrienes contribute to the pathophysiology of asthma, especially in patients with aspirin-exacerbated respiratory disease (AERD), and cause or potentiate the following symptoms:
=== Small RNA molecules regulate gene expression by post-transcriptional gene silencing === Another previously unknown mechanism by which RNA molecules are involved in genetic regulation was discovered in the 1990s. Small RNA molecules termed microRNA (miRNA) and small interfering RNA (siRNA) are abundant in eukaryotic cells and exert post-transcriptional control over mRNA expression. They function by binding to specific sites within the mRNA and inducing cleavage of the mRNA via a specific silencing-associated RNA degradation pathway.
This is a list of casual dining restaurant chains around the world, arranged in alphabetical order. A casual dining restaurant is a restaurant that serves moderately priced food in a casual atmosphere. Except for buffet-style restaurants and, more recently, fast casual restaurants, casual dining restaurants usually provide table service.
Sources: en.wikipedia.org
===== Digital wallet scheme ===== Paetongtarn has overseen the implementation of the 10,000-baht digital wallet scheme, the flagship economic policy of the Pheu Thai Party. The scheme was originally promised during the 2023 election campaign as a one-time universal handout to nearly all Thais aged 16 and over, intended to deliver a large-scale stimulus to the domestic economy. However, since the Paetongtarn government took office, the program has faced significant modifications, delays, and criticism regarding its funding, implementation, and economic necessity. The initial plan to fund the 500 billion baht scheme through a special loan bill was scrapped due to legal concerns and fears of violating fiscal discipline laws. Instead, the government has relied on the national budget. The universal nature of the handout was also curtailed, with eligibility restrictions introduced to exclude high-income earners (those with an annual income over 840,000 baht) and individuals with more than 500,000 baht in savings. Phase 1, launched in September 2024, provided 10,000 baht in cash to approximately 14.5 million recipients, including state welfare cardholders and individuals with disabilities. Phase 2, implemented between January and April 2025, extended the cash transfers to an estimated 3 million senior citizens aged 60 and over. The first truly "digital" phase, which was set to target around 2.7 million young people aged 16–20 via a government application, has been indefinitely postponed.
prostacyclin synthase to create prostacyclin thromboxane-A synthase to create thromboxane A2 and 12-(S)-hydroxy-5Z,8E,10E-heptadecatrienoic acid (HHT) (see 12-Hydroxyheptadecatrienoic acid) prostaglandin D2 synthase to create prostaglandin D2 prostaglandin E synthase to create prostaglandin E2 prostaglandin F synthase to create prostaglandin F2α It rearranges non-enzymatically to:
==== Books ==== In the 1942 short story "Funes the Memorious" by Jorge Luis Borges, the protagonist suffers a head injury after which he gains the ability to remember every detail of what he experiences, but comes to view this as a curse. In the 1980 series The Book of the New Sun by Gene Wolfe, the protagonist remembers everything he has ever seen starting from infancy. He describes his memories as being so vivid that he is capable of re-living anything he has experienced whenever he chooses to do so. In a 2011 manga by Kohske called Gangsta, the main character, Worick Arcangelo, is said to have hyperthymesia, which he uses to help police identify murder victims. In the 2015 novel Memory Man by David Baldacci, the protagonist, Amos Decker, has hyperthymesia. In the book, a mystery-crime scene-thriller with graphic scenes, Decker uses his perfect memory brought on by a traumatic hit in football to solve the murder of his wife and child, and the school shooting connected to it. Decker recalls his memories as a "DVR", just playing when it wants to, or being rewound and played forward by conscious thought. In the 2021 romantic suspense series Memento Mori by C.S. Poe, the protagonist, Everett Larkin, has hyperthymesia. Larkin suffered a traumatic brain injury at the age of 18, leaving him with highly superior autobiographical memory (HSAM) but very poor short-term memory. He remembers events since his injury with perfect recall, and memories are often brought to the surface through "associations." Larkin uses his superior memory as a detective on the NYPD cold case squad.
Sources: en.wikipedia.org
=== Notable individuals === Arthur Heffter isolated mescaline from peyote and discovered its psychedelic effects via self-experimentation. He published these findings in 1898. Heffter was the first person to experience psychedelic effects with a pure psychedelic compound. Silas Weir Mitchell was one of the first to experiment with mescaline, as peyote, and published his experience in 1896. Havelock Ellis was the author of one of the first written reports to the public about an experience with mescaline (1898). William James was one of the first to experiment with mescaline, as peyote. However, he took a low dose (1 peyote button), became violently ill for 2 days, and experienced no other effects. He opted not to retry the drug. James tried peyote in 1896 but his experience was not published until decades later. Jean-Paul Sartre took mescaline shortly before the publication of his book, L'Imaginaire (1940); he had a bad trip during which he imagined that he was menaced by sea creatures. For many years following this, he persistently imagined that he was being followed by lobster- or crab-like creatures, and became a patient of Jacques Lacan in hopes of being rid of them. Lobsters and crabs figure in his novel Nausea (1938). Salvador Dalí has been persistently rumored to have taken psychedelics such as mescaline. However, in response to these rumors, Dalí famously exclaimed "I don't do drugs. I am drugs!" in 1982. Antonin Artaud wrote 1947's The Peyote Dance, where he describes his peyote experiences in Mexico a decade earlier. Allen Ginsberg took peyote.
In 1996, it became a contract research organization (CRO) for the biopharmaceutical sector and entered into collaboration with SmithKline Beecham biologicals (Rixensart, Belgium) for the production of recombinant proteins for phase I, II and III clinical trials. In addition to its pharmaceutical manufacturing activities, Eurogentec became a service company for the biotechnical research industry and university laboratories. In 1999, Eurogentec acquired Oswel Research Product Ltd. a biotechnology company based in Southampton, Great Britain and specialized in the synthesis of chemically modified and complex oligonucleotides and their analogues (DNA, RNA, PNA). In 2002, Eurogentec acquired Wita Proteomics, a company specialized in proteomics services, based in Berlin (Germany). A few months later, Eurogentec installed its US office in San Diego for the production of oligonucleotides (EGT NA).
== External links == "Opioid Receptors: κ". The International Union of Basic and Clinical Pharmacology, The British Pharmacological Society, The University of Edinburgh. International Union of Basic and Clinical Pharmacology. Archived from the original on 2014-02-23. Retrieved 2007-07-23. kappa+Opioid+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.